SYN004 / Synermore  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SYN004 / Synermore
SYN004_Ph_1, NCT02391727: Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors

Completed
1
10
US
SYN004
Synermore Biologics Co., Ltd.
Colon Cancer, Breast Cancer, Cancer of the Head and Neck
10/18
10/18
NCT04363242: A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions

Active, not recruiting
1
22
US
SYN125, SYN004
Synermore Biologics Co., Ltd., Synermore Biologics USA Limited
Epithelial Carcinoma, Solid Tumor
07/23
09/23

Download Options